Elizabeth Chandler, NP
Adult Health · Baltimore, MDNPI 1144477472
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,363 of the $17,093 with a category attached, or 72.3%. AbbVie accounts for 63.4% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $10,997, more than ten times the $446 reported in 2021. Among adult health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $104.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Pfizer$4K
- Ipsen Innovation$745
- Biogen$527
- Lundbeck LLC$243
- Eisai Inc.$219
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$12,36372%
- Travel & lodging$5753%
- Food & beverage$4,15624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 71 | $10,832 |
| Pfizer | 8 | $3,517 |
| Ipsen Innovation | 5 | $745 |
| Biogen | 26 | $527 |
| Lundbeck LLC | 6 | $243 |
| Eisai Inc. | 8 | $219 |
| Incyte Corporation | 1 | $121 |
| Genentech USA, Inc. | 5 | $116 |
| Amgen(2 entities) | 5 | $116 |
| Lilly USA, LLC | 6 | $112 |
| Johnson & Johnson(2 entities) | 3 | $80 |
| SK Life Science, Inc. | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 2 | $60 |
| Biohaven Pharmaceuticals, Inc. | 1 | $50 |
| Sanofi | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $42 |
| Acadia Pharmaceuticals Inc | 2 | $41 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Banner Life Sciences, LLC | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Avion Pharmaceuticals | 1 | $16 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,093 in reported general payments places this provider in the 95th percentile of 542 adult health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 16 | $150,127 |
| TecfideraDimethyl Fumarate | 15 | $131,553 |
| Emgality PenGalcanezumab-Gnlm | 83 | $68,709 |
| QuliptaAtogepant | 53 | $63,163 |
| UbrelvyUbrogepant | 44 | $57,770 |
| Nurtec OdtRimegepant Sulfate | 44 | $52,167 |
| Aimovig AutoinjectorErenumab-Aooe | 38 | $33,309 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,350 |
| Dimethyl Fumarate | 14 | $3,178 |
| Eletriptan HbrEletriptan Hydrobromide | 12 | $1,241 |
| Gabapentin | 36 | $826 |
| RizatriptanRizatriptan Benzoate | 25 | $560 |
| Topiramate | 38 | $532 |
| Baclofen | 18 | $366 |
| Duloxetine Hcl | 12 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $44 | $150,12716 claims |
| BiogenTecfidera | $527 | $131,55315 claims |
| AbbVieQulipta, Ubrelvy | $10,832 | $120,93297 claims |
| PfizerNurtec Odt | $3,517 | $52,16744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 adult health providers in Maryland.
Other adult health in Baltimore
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Sarah RileyBaltimore$24K
- Monica LovinsBaltimore$18K
- Clifton DawsonBaltimore$14K
- Selina YeasminBaltimore$8K
- Andrea ArroyoBaltimore$8K
- Kathleen CostelloBaltimore$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.